{"id":41185,"date":"2025-09-11T17:00:24","date_gmt":"2025-09-11T09:00:24","guid":{"rendered":"https:\/\/flcube.com\/?p=41185"},"modified":"2025-09-11T17:00:25","modified_gmt":"2025-09-11T09:00:25","slug":"genfleet-therapeutics-surges-onto-hong-kong-main-board-raising-hk1-58-b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41185","title":{"rendered":"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB"},"content":{"rendered":"\n<p>China\u2011based <strong>GenFleet Therapeutics (Shanghai)\u202fInc.<\/strong> (HKG: 2595) completed a successful <strong>initial public offering (IPO)<\/strong> on the Hong Kong Stock Exchange\u2019s Main Board. The company offered <strong>77,600,000 H\u2011shares<\/strong> at <strong>HK$20.39 per share<\/strong>, generating a gross proceeds of <strong>HK$1.582\u202fbillion<\/strong> and net proceeds of <strong>HK$1.444\u202fbillion<\/strong> after underwriting fees.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-highlights\">IPO Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Shares Issued<\/strong><\/td><td>77.6\u202fmillion H\u2011shares<\/td><\/tr><tr><td><strong>Offer Price<\/strong><\/td><td>HK$20.39 \/ share<\/td><\/tr><tr><td><strong>Gross Proceeds<\/strong><\/td><td>HK$1.582\u202fbillion<\/td><\/tr><tr><td><strong>Net Proceeds<\/strong><\/td><td>HK$1.444\u202fbillion<\/td><\/tr><tr><td><strong>Listing Date<\/strong><\/td><td>11\u202fSep\u202f2025<\/td><\/tr><tr><td><strong>Ticker<\/strong><\/td><td>2595.HK<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-snapshot\">Company Snapshot<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded<\/strong>: 2017, based in Shanghai<\/li>\n\n\n\n<li><strong>Stage<\/strong>: Clinical\u2011stage biopharma focused on oncology, autoimmune and inflammatory diseases<\/li>\n\n\n\n<li><strong>Pipeline<\/strong>: 8 candidates, 5 in clinical development (GFH925, GFH375, GFS202A, GFH312, others)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-core-products\">Core Products<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Target<\/th><th>Status<\/th><th>Notable Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>GFH925 (Fulzerasib)<\/strong><\/td><td>KRAS\u202fG12C inhibitor<\/td><td>Approved in China (Dec\u202f2023)<\/td><td>First KRAS\u202fG12C inhibitor approved in China for advanced NSCLC post\u2011standard therapy<\/td><\/tr><tr><td><strong>GFH375<\/strong><\/td><td>KRAS\u202fG12D inhibitor<\/td><td>Phase\u202fI\/II in China<\/td><td>Investigated in advanced solid tumors harboring KRAS\u202fG12D mutation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-other-novel-target-programs\">Other Novel\u2011Target Programs<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GFS202A<\/strong> \u2013 GDF15\/IL\u20116 bispecific antibody (BsAb)<\/li>\n\n\n\n<li><strong>GFH312<\/strong> \u2013 RIPK1 kinase inhibitor<\/li>\n\n\n\n<li>Additional candidates targeting inflammatory pathways and solid tumor antigens<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-overview-2023-q1-2025\">Financial Overview (2023\u2011Q1\u202f2025)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Period<\/th><th>Revenue (RMB\u202fmillion)<\/th><th>Net Loss (RMB\u202fmillion)<\/th><\/tr><\/thead><tbody><tr><td>2023<\/td><td>73.73<\/td><td>508<\/td><\/tr><tr><td>2024<\/td><td>105<\/td><td>678<\/td><\/tr><tr><td>Q1\u202f2025<\/td><td>82.15<\/td><td>66.62<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>The company continues to invest heavily in R&amp;D, driving the net loss figures.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Infusion<\/strong> \u2013 The IPO provides GenFleet with a robust capital base to accelerate pipeline development and potentially expand into new therapeutic areas.<\/li>\n\n\n\n<li><strong>KRAS Focus<\/strong> \u2013 As the first Chinese\u2011approved KRAS\u202fG12C inhibitor, GenFleet is positioned to capture a rapidly growing precision\u2011medicine market.<\/li>\n\n\n\n<li><strong>Investor Sentiment<\/strong> \u2013 Strong demand for the shares reflects confidence in GenFleet\u2019s technology platform and pipeline, especially its dose\u2011adjustable bispecific antibody and kinase inhibitor programs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025091100032_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025091100032_c.\"><\/object><a id=\"wp-block-file--media-f3a88cf2-32d7-4f76-9459-629cb2043c9c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025091100032_c.pdf\">2025091100032_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025091100032_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f3a88cf2-32d7-4f76-9459-629cb2043c9c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based GenFleet Therapeutics (Shanghai)\u202fInc. (HKG: 2595) completed a successful initial public offering (IPO) on the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41187,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,4345,72],"class_list":["post-41185","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-hkg-2595","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based GenFleet Therapeutics (Shanghai)\u202fInc. (HKG: 2595) completed a successful initial public offering (IPO) on the Hong Kong Stock Exchange\u2019s Main Board. The company offered 77,600,000 H\u2011shares at HK$20.39 per share, generating a gross proceeds of HK$1.582\u202fbillion and net proceeds of HK$1.444\u202fbillion after underwriting fees.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41185\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB\" \/>\n<meta property=\"og:description\" content=\"China\u2011based GenFleet Therapeutics (Shanghai)\u202fInc. (HKG: 2595) completed a successful initial public offering (IPO) on the Hong Kong Stock Exchange\u2019s Main Board. The company offered 77,600,000 H\u2011shares at HK$20.39 per share, generating a gross proceeds of HK$1.582\u202fbillion and net proceeds of HK$1.444\u202fbillion after underwriting fees.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41185\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-11T09:00:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-11T09:00:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1111.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB\",\"datePublished\":\"2025-09-11T09:00:24+00:00\",\"dateModified\":\"2025-09-11T09:00:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185\"},\"wordCount\":293,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1111.webp\",\"keywords\":[\"Biotech\",\"HKG: 2595\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41185#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41185\",\"name\":\"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1111.webp\",\"datePublished\":\"2025-09-11T09:00:24+00:00\",\"dateModified\":\"2025-09-11T09:00:25+00:00\",\"description\":\"China\u2011based GenFleet Therapeutics (Shanghai)\u202fInc. (HKG: 2595) completed a successful initial public offering (IPO) on the Hong Kong Stock Exchange\u2019s Main Board. The company offered 77,600,000 H\u2011shares at HK$20.39 per share, generating a gross proceeds of HK$1.582\u202fbillion and net proceeds of HK$1.444\u202fbillion after underwriting fees.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41185\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1111.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1111.webp\",\"width\":1080,\"height\":608,\"caption\":\"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41185#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based GenFleet Therapeutics (Shanghai)\u202fInc. (HKG: 2595) completed a successful initial public offering (IPO) on the Hong Kong Stock Exchange\u2019s Main Board. The company offered 77,600,000 H\u2011shares at HK$20.39 per share, generating a gross proceeds of HK$1.582\u202fbillion and net proceeds of HK$1.444\u202fbillion after underwriting fees.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41185","og_locale":"en_US","og_type":"article","og_title":"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB","og_description":"China\u2011based GenFleet Therapeutics (Shanghai)\u202fInc. (HKG: 2595) completed a successful initial public offering (IPO) on the Hong Kong Stock Exchange\u2019s Main Board. The company offered 77,600,000 H\u2011shares at HK$20.39 per share, generating a gross proceeds of HK$1.582\u202fbillion and net proceeds of HK$1.444\u202fbillion after underwriting fees.","og_url":"https:\/\/flcube.com\/?p=41185","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-11T09:00:24+00:00","article_modified_time":"2025-09-11T09:00:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1111.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41185#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41185"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB","datePublished":"2025-09-11T09:00:24+00:00","dateModified":"2025-09-11T09:00:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41185"},"wordCount":293,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41185#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1111.webp","keywords":["Biotech","HKG: 2595","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41185#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41185","url":"https:\/\/flcube.com\/?p=41185","name":"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41185#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41185#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1111.webp","datePublished":"2025-09-11T09:00:24+00:00","dateModified":"2025-09-11T09:00:25+00:00","description":"China\u2011based GenFleet Therapeutics (Shanghai)\u202fInc. (HKG: 2595) completed a successful initial public offering (IPO) on the Hong Kong Stock Exchange\u2019s Main Board. The company offered 77,600,000 H\u2011shares at HK$20.39 per share, generating a gross proceeds of HK$1.582\u202fbillion and net proceeds of HK$1.444\u202fbillion after underwriting fees.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41185#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41185"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41185#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1111.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1111.webp","width":1080,"height":608,"caption":"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41185#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58\u202fB"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1111.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41185"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41185\/revisions"}],"predecessor-version":[{"id":41188,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41185\/revisions\/41188"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41187"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}